Biocon to obtain approval for diabetes drug, Liraglutide in UK
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Subscribe To Our Newsletter & Stay Updated